Telomerase reverse transcriptase (TERT) is essential for tumor proliferation and is an attractive therapeutic target. Non-invasive methods of imaging TERT can report on tumor proliferation and response to therapy. Here, we show that 2H-MRS following administration of [U-2H]pyruvate non-invasively monitors TERT expression in clinically relevant patient-derived glioma models. Importantly, imaging TERT using [U-2H]pyruvate provides a readout of response to targeted TERT inhibitors and standard of care chemotherapy in vivo, at early timepoints that precedes MRI-detectable anatomical alterations. Clinical translation of our results can enable non-invasive assessment of TERT expression in vivo and, thereby, aid in imaging response to anti-cancer therapies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords